Abstract:Molecular hybridization is a powerful strategy in drug discovery. A series of novel diarylbenzopyrimidine (DABP) analogues were developed by the hybridization of FDA-approved drugs etravirine (ETR) and efavirenz (EFV) as potential HIV-1 nonnudeoside reverse transcriptase inhibitors (NNRTIs). Substituent modifications resulted in the identification of new DABPs with the combination of the strengths of the two drugs, especially compound lid, which showed promising activity toward the EFV-resistant K103N mutant. 12d also had a favorable pharmacokinetic (PK) profile with liver microsome clearances of 14.4 mu L/min/mg (human) and 33.2 mu L/min/mg (rat) and an oral bioavailability of 15.5% in rat. However, its activity against the E138K mutant was still unsatisfactory; E138K is the most prevalent NNRTI resistance-associated mutant in ETR treatment Further optimizations resulted in a highly potent compound (12z) with no substituents on the phenyl ring and a 2-methyl-6-nitro substitution pattern on the 4-cyanovinyl-2,6-disubstitued phenyl motif. The antiviral activity of this compound was much higher than those of ETR and EFV against the WT, E138K, and K103N variants (EC50 = 3.4, 4.3, and 3.6 nM, respectively), and the cytotoxicity was decreased while the selectivity index (SI) was increased. In particular, this compound exhibited acceptable intrinsic liver microsome stability (human, 34.5 mu L/min/mg; rat, 33.2 mu L/min/mg) and maintained the good PK profile of its parent compound EFV and showed an oral bioavailability of 16.5% in rat. Molecular docking and structure-activity relationship (SAR) analysis provided further insights into the binding of the DABPs with HIV-1 reverse transcriptase and provided a deeper understanding of the key structural features responsible for their interactions.

Targeting the Hydrophobic Channel of NNIBP: Discovery of Novel 1,2,3-Triazole-derived Diarylpyrimidines As Novel HIV-1 NNRTIs with High Potency Against Wild-Type and K103N Mutant Virus

Targeting the Entrance Channel of NNIBP: Discovery of Diarylnicotinamide 1,4-Disubstituted 1,2,3-Triazoles As Novel HIV-1 NNRTIs with High Potency Against Wild-Type and E138K Mutant Virus

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives Targeting the Entrance Channel of NNRTI Binding Pocket.

Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses

Discovery of Novel Diarylpyrimidine Derivatives As Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation

Discovery of Novel Diarylpyrimidines As Potent HIV-1 NNRTIs by Investigating the Chemical Space of a Less Explored "hydrophobic Channel"

Exploring the Hydrophobic Channel of NNIBP Leads to the Discovery of Novel Piperidine-Substituted Thiophene[3,2-D]pyrimidine Derivatives As Potent HIV-1 NNRTIs

Discovery of Novel Fused-heterocycle-bearing Diarypyrimidine Derivatives As HIV-1 Potent NNRTIs Targeting Tolerant Region I for Enhanced Antiviral Activity and Resistance Profile

Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles

Design, Synthesis and Evaluation of Novel HIV-1 NNRTIs with Dual Structural Conformations Targeting the Entrance Channel of the NNRTI Binding Pocket

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity Against K103N and E138K Mutants and Pharmacokinetic Profiles

Fused Heterocycles Bearing Bridgehead Nitrogen As Potent Hiv-1 Nnrtis. Part 2: Discovery of Novel [1,2,4]Triazolo[1,5-A]pyrimidines Using A Structure-Guided Core-Refining Approach

Development of Novel Dihydrofuro[3,4- d ]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C

Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3- d ]pyrimidine derivatives as novel HIV-1 NNRTIs

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylnicotinamide Derivatives (danas) Targeting the Entrance Channel of the NNRTI Binding Pocket Through Structure-Guided Molecular Hybridization

Design, Synthesis and Biological Evaluation of 3-Benzyloxy-linked Pyrimidinylphenylamine Derivatives As Potent HIV-1 NNRTIs.

Structure-Based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent Hiv-1 Nnrtis

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants